1Otake Takeshi. Present condition of LPG national stockpiling as main part's undergroud cavern of water sealing J]. Journal of the Japanese Association for Petrleum Technology, 2000, 66(2) : 183 - 193.
2Otake Takeshi, Hashimoto Nobuo. Big underground opening, the key issues for ensuring the water sealing system of LPG underground rock caverns[J]. Tsuchi to Kiso, 1998,46(6) : 9- 12.
3Uehara MH, Kohlmann NE,Zanella MT,et al. Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab, 2001,3: 319-325.
4Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA, 2003,289: 2560-2572.
5The STOP-NIDDM Trial. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA, 2003,290: 486-494.
6Pahor M. Therapeutic benefits of ACE inhibitor and other antihypertensive drugs in patients with type 2 diabetes. Diabtes Care,2000,23:888-892.
7Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New Engl J Med,2001,345:851-860.
8Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001,345: 861-869.
9Tuomilehto J, Rastenyte D, Birkenhagar WH, et al. For the Systolic Hypertension in Europe Trial investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med, 1999,340:677-684.
10ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertension patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack
